贵阳新天药业股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 21 日披露了《关于控股股东拟减持公司股份的预披露公告》（公告编号：2025-056）， 持有公司股份75,485,566股（占剔除公司回购专用账户中股份后总股本的32.0809%） 的控股股东上海新天智药生物技术有限公司（以下简称"新天智药"）计划通过大 宗交易和集中竞价交易方式减持其持有的本公司股份合计不超过 7,050,000 股，占剔 除公司回购专用账户中股份后总股本的比例为 2.9962%（其中：通过大宗交易方式 减持公司股份不超过 4,700,000 股，占其持有公司股份总数的 6.2264%，占剔除公司 回购专用账户中股份后总股本的 1.9975%；通过集中竞价交易方式减持公司股份不 超过 2,350,000 股，占其持有公司股份总数的 3.1132%，占剔除公司回购专用账户中 股份后总股本的 0.9987%）。 公司于 2025 年 11 月 14 日披露了《关于控股股东减持股份触及 1%的公告》（公 告编号：2025-058），新天智药通过集中竞价交易方式减持公司股份 800,000 股， 占剔除公司回购专用 ...

Core Viewpoint - New Tian Pharmaceutical's stock rose by 2.27% to a closing price of 10.80 yuan, with significant block trades occurring on November 25 [1] Trading Activity - A total of three block trades were executed, with a combined trading volume of 633,000 shares and a total transaction value of 6.0135 million yuan [1] - The first trade had a price of 9.50 yuan for 211,000 shares, amounting to 2.0045 million yuan, with a discount rate of -12.04% [1] - The second trade mirrored the first, also at 9.50 yuan for 211,000 shares and a transaction value of 2.0045 million yuan, with the same discount rate [1] - The third trade was identical in price and volume, executed at 9.50 yuan for 211,000 shares, totaling 2.0045 million yuan, with the buyer being a different brokerage [1] Recent Performance - Over the past three months, the stock has seen a total of three block trades with a cumulative transaction value of 6.0135 million yuan [1] - In the last five trading days, the stock has declined by 3.91%, with a net outflow of 4.9137 million yuan in principal funds [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-11-25 | 002873 | 新天药业 | 9.50 | 21.10 | | 200.45 机构专用 | 华创证券有限责任 | | | | | | | | | 公司深圳香梅路证 | | | | | | | | | 券营业部 | | 2025-11-25 | 002873 | 新天药业 | 9.50 | 21.10 | | 200.45 机构专用 | 华创证券有限责任 | | | | | | | | | 公司深圳香梅路证 | | | | | | | | | 劳营业部 | | 2025-11-25 | 002873 | 新天药业 | 9.50 | 21.10 | | 200.45 华泰证券股份有限 | 华创证券有限责任 | | | | | | | | 公司广东分公司 | 公司深圳香梅路证 | | | | | | ...

Group 1 - New Tian Pharmaceutical announced that as of the date of the announcement, New Tian Zhi Pharmaceutical has pledged approximately 48.04 million shares, accounting for 64.99% of its total holdings [1] - For the first half of 2025, New Tian Pharmaceutical's revenue composition is as follows: main business revenue accounts for 99.9%, while other business revenue accounts for 0.1% [1] - The current market capitalization of New Tian Pharmaceutical is 2.8 billion yuan [2]

证券代码：002873 证券简称：新天药业 公告编号：2025-059 贵阳新天药业股份有限公司 关于控股股东质押股份并解除部分质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）近日收到控股股东上海新 天智药生物技术有限公司（以下简称"新天智药"）的通知，新天智药对其持有 的公司部分股份进行了质押，并对部分已质押股份办理了解除质押手续，具体情 况如下： | 股东 | 是否控股 股东及一 | 本次质 押数量 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否 为补 | 质押 起始 | 质押 到期 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 致行动人 | （股） | 比例 | 比例 | 限售股 | 充质 | 日 | 日 | | 用途 | | | | | | | | 押 | | | | | | 新天 | 是 | 2,430,00 | 3.29% | 1.00% | 否 | ...

Group 1 - The core point of the article is that the controlling shareholder of New Tian Pharmaceutical, Shanghai New Tian Zhi Pharmaceutical Biotechnology Co., Ltd., reduced its stake by selling 800,000 shares, which represents 0.3277% of the total share capital [1] - The average selling price of the shares was 11.29 yuan per share, amounting to approximately 9.03 million yuan [1] - Following the reduction, the controlling shareholder's ownership percentage decreased from 32.0809% to 31.7409%, maintaining its position as the largest shareholder of the company [1]

Core Viewpoint - The controlling shareholder of Guizhou Xintian Pharmaceutical Co., Ltd. plans to reduce its shareholding, which has triggered a notification due to the change in equity ratio reaching 1% [1][2]. Shareholder Reduction Details - The controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., holds 75,485,566 shares, accounting for 32.0809% of the total share capital after excluding shares in the repurchase account [2]. - The planned reduction includes a maximum of 7,050,000 shares, representing 2.9962% of the total share capital after excluding shares in the repurchase account. This consists of up to 4,700,000 shares through block trading (6.2264% of its total shares) and up to 2,350,000 shares through centralized bidding (3.1132% of its total shares) [2]. - As of November 12, 2025, the controlling shareholder has reduced its holdings by 800,000 shares, which is 0.3277% of the total share capital, bringing its total holdings to 74,685,566 shares and reducing its ownership percentage to 31.7409% [2]. Equity Change Notification - The reduction in shareholding has triggered a notification as the equity change has reached 1% [3].

（文章来源：证券日报） 证券日报网讯 11月13日晚间，新天药业发布公告称，近日，公司收到持有公司股份75，485，566股 （占剔除公司回购专用账户中股份后总股本的32.0809%）的控股股东上海新天智药生物技术有限公司 （以下简称"新天智药"）出具的《减持股份数量触及1%的告知函》，截至2025年11月12日，新天智药 已通过集中竞价交易方式减持公司股份共计800，000股，占公司总股本0.3277%，占剔除公司回购专用 账户中股份后总股本的比例为0.3400%。本次减持后，新天智药持有公司股份74，685，566股，持股比 例由32.0809%下降至31.7409%，权益变动触及1%。 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 贵阳新天药业股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 21 日披露了《关于控股股东拟减持公司股份的预披露公告》（公告编号：2025-056）， 具体内容详见巨潮资讯网（http://www.cninfo.com.cn）、《证券时报》等公司指定 信息披露媒体。 持有公司股份 75,485,566 股（占剔除公司回购专用账户中股份后总股本的 32.0809%）的控股股东上海新天智药生物技术有限公司（以下简称"新天智药"） 计划通过大宗交易和集中竞价交易方式减持其持有的本公司股份合计不超过 7,050,000 股，占剔除公司回购专用账户中股份后总股本的比例为 2.9962%（其中： 通过大宗交易方式减持公司股份不超过 4,700,000 股，占其持有公司股份总数的 6.2264%，占剔除公司回购专用账户中股份后总股本的 1.9975%；通过集中竞价交易 方式减持公司股份不超过 2,350,000 股，占其持有公司股份总数的 3.1132%，占剔除 公司回购专用账户中股份后总股本的 0.9987%）。 近日，公司收到新天 ...

Core Viewpoint - The company Xintian Pharmaceutical announced that its controlling shareholder, Xintian Zhiyao, plans to reduce its holdings by no more than 7.05 million shares, accounting for 2.9962% of the total share capital after excluding shares in the repurchase special account [1] Summary by Sections - **Shareholding Reduction Plan** - Xintian Zhiyao intends to reduce its stake by up to 7.05 million shares, which represents 2.9962% of the total share capital after excluding repurchased shares [1] - **Current Status of Share Reduction** - As of November 12, Xintian Zhiyao has already reduced its holdings by 800,000 shares, which is 0.3277% of the total share capital and 0.3400% of the total share capital after excluding repurchased shares [1] - **Impact on Shareholding Percentage** - Following this reduction, Xintian Zhiyao's shareholding percentage decreased from 32.0809% to 31.7409%, with the change in equity reaching 1%, consistent with previous reduction plans and commitments [1]